Not Yet Registered?
|
|
Release date: December 31, 2006
Date of most recent review: December 31, 2007
Available for credit through: June 30, 2008
PROGRAM DESCRIPTION:
While there are standard treatment paradigms for patients with multiple myeloma, the majority of patients eventually relapse. A number of new agents, including the immunomodulatory agents thalidomide and lenalidomide, and the proteasome inhibitor bortezomib, have demonstrated impressive response rates in combination with established regimens and offer new hope for patients. The new clinical data emerging include the use of these agents in front-line and relapsed settings, in a range of combination regimens, and in high-risk patients (including those with renal dysfunction, chromosomal deletions, etc.). However, these new efficacy data, in addition to the associated safety results, can be overwhelming and confusing to busy physicians.
The CME Case Continuum is a dynamic, interactive, Web-based learning program in which participants are able to review case studies written by experts in the field of multiple myeloma. In order to receive CME credits, you may review up to 6 case studies. In addition to reviewing case studies, participants may create and submit their own case study for review by the faculty. CME credits will be given for submission of each case. To participate in any part of the case-based learning program, you must register and be “signed in.”
EDUCATIONAL OBJECTIVES:
Upon completion of this program, participants should be better able to:
- Identify the comprehensive parameters involved in treating patients diagnosed with multiple myeloma
- Evaluate challenging case studies that will engage and enhance learnings and practice behavior
- Discuss potentially new treatments in ways they may not have conceived previously
- Recognize new pathologies through online interaction with colleagues
ACCREDITATION
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of ArcMesa Educators and Fission Communications. ArcMesa Educators is accredited by the ACCME to provide continuing medical education for physicians.
ArcMesa Educators designates this educational activity for a maximum of 8 AMA PRA Category 1 Credits™.
DISCLOSURE POLICY
It is the policy of ArcMesa Educators to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty are expected to disclose any relevant financial relationships they may have with commercial interests in relation to this activity. These relationships, along with the educational content of this program, have been reviewed and any potential conflicts of interest have been resolved to the satisfaction of ArcMesa Educators. The staff of ArcMesa have nothing to disclose.
FACULTY DISCLOSURE DECLARATIONS
Sundar Jagannath, MD
Has the following to disclose:
Celgene; Advisory Board
Millennium; Advisory Board
Genentech; Advisory Board
Robert Z. Orlowski, MD, PhD
Has the following to disclose:
Millennium; Advisory Board
Ortho Biotech; Advisory Board
Paul G. Richardson, MD
Has the following to disclose:
Celgene; Speakers Bureau, Advisory Board
Millennium; Speakers Bureau, Advisory Board
|
|
Sundar Jagannath, MD
Chief of the Multiple Myeloma and Bone Marrow Transplantation Program
Saint Vincent’s Comprehensive Cancer Center
New York, New York
Professor of Medicine
New York Medical College
Valhalla, New York
Robert Z. Orlowski, MD, PhD Lenvel Lee Rothrock Associate Professor of Medicine
Division of Hematology / Oncology and Pharmacology
University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
Paul G. Richardson, MD
Associate Professor of Medicine
Harvard Medical School
Clinical Director, Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts
|
|